Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

ClinicalTrials.gov ID: NCT01732926

Public ClinicalTrials.gov record NCT01732926. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Study identification

NCT ID
NCT01732926
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Gilead Sciences
Industry
Enrollment
475 participants

Conditions and interventions

Interventions

  • Idelalisib Drug
  • Rituximab Drug
  • Bendamustine Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 1, 2013
Primary completion
May 16, 2016
Completion
May 16, 2016
Last update posted
Nov 15, 2018

2013 – 2016

United States locations

U.S. sites
33
U.S. states
14
U.S. cities
33
Facility City State ZIP Site status
Clearview Cancer Institute Huntsville Alabama 35805
Ironwood Cancer and Research Center Chandler Arizona 85224
Comprehensive Blood and Cancer Center (Bakersfield) Bakersfield California 93309
Saint Jude Heritage Healthcare (TORI) Fullerton California 92835
Pacific Shores Medical Group Long Beach California 90813
Cancer Care Associates Redondo Beach California 90277
San Luis Obispo Oncology and Hematology San Luis Obispo California 93401
Cancer Center of Santa Barbara Santa Barbara California 93105
Central Coast Medical Oncology Group Santa Maria California 93454
St Joseph Heritage Healthcare System Santa Rosa California 95403
Kaiser Permanente Vallejo Medical Center Vallejo California 94589
Sylvester Comprehensive Cancer Center/UMHC Deerfield Beach Florida 33442
Cancer Specialists of North Florida Jacksonville Florida 32256
Northwest Georgia Oncology Centers, PC Marietta Georgia 30060
Rush University Medical Center Chicago Illinois 60612
Joliet Oncology Hematology Associates Ltd. Joliet Illinois 60435
Cancer Center of Kansas Wichita Kansas 67214
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901
North Shore Hematology/Oncology Associates East Setauket New York 11733
Weill Cornell Medical College New York New York 10065
Signal Point Clinical Research Center, LLC Middletown Ohio 45042
Hollings Cancer Center Charleston South Carolina 29425
Bon Secours Saint Francis Hospital Greenville South Carolina 29607
Texas Oncology, P.A. Bedford Texas 76022
Charles A. Sammons Cancer Center Dallas Texas 75246
Texas Oncology, P.A. Denton Texas 76210
Brooke Army Medical Center Fort Sam Houston Texas 78234
Texas Oncology, P.A. Harlingen Texas 78550-8321
Texas Oncology, P.A. Weslaco Texas 78596-6608
Swedish Medical Center Seattle Washington 98104
Northwest Medical Specialists Tacoma Washington 98405
Aurora BayCare Medical Center Green Bay Wisconsin 54308
Froedtert Hospital and Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 111 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01732926, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 15, 2018 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01732926 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →